Distribuzione geografica
Continente #
NA - Nord America 9.662
EU - Europa 2.900
AS - Asia 1.076
SA - Sud America 61
AF - Africa 56
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.760
Nazione #
US - Stati Uniti d'America 9.599
SE - Svezia 887
IT - Italia 836
IN - India 542
CN - Cina 475
FI - Finlandia 303
UA - Ucraina 262
DE - Germania 191
RO - Romania 119
GB - Regno Unito 90
CA - Canada 63
BG - Bulgaria 56
AR - Argentina 55
SG - Singapore 43
IE - Irlanda 40
TG - Togo 40
GR - Grecia 24
FR - Francia 21
NL - Olanda 21
BE - Belgio 20
ZA - Sudafrica 10
AT - Austria 7
CH - Svizzera 7
CL - Cile 4
IL - Israele 4
RU - Federazione Russa 4
AU - Australia 3
RS - Serbia 3
SC - Seychelles 3
BR - Brasile 2
EG - Egitto 2
ES - Italia 2
EU - Europa 2
HK - Hong Kong 2
JP - Giappone 2
LT - Lituania 2
TR - Turchia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
LI - Liechtenstein 1
MA - Marocco 1
MK - Macedonia 1
PH - Filippine 1
SA - Arabia Saudita 1
Totale 13.760
Città #
Fairfield 1.640
Chandler 731
Ashburn 725
Woodbridge 688
Seattle 637
Wilmington 598
Houston 572
Cambridge 539
Ann Arbor 366
Princeton 343
Beijing 328
Rome 328
Plano 265
San Paolo di Civitate 243
Boston 182
Lawrence 172
Dearborn 169
San Diego 113
Jacksonville 108
Millbury 101
Bremen 99
Des Moines 83
Andover 81
New York 68
Sofia 55
Helsinki 52
Federal 51
Norwalk 51
Toronto 43
Dublin 40
Lomé 40
Southend 38
San Mateo 36
Boardman 34
Falls Church 27
Hefei 20
Brussels 19
Nanjing 17
Florence 16
Kunming 14
Ottawa 12
Guangzhou 10
Redmond 10
Bologna 9
Milan 9
Naples 9
Fremont 8
Indiana 8
Auburn Hills 7
Bühl 7
Fasano 7
Paris 7
Phoenix 7
Pune 7
Singapore 7
Buffalo 6
Laurel 6
London 6
Los Angeles 6
Nanchang 6
Nuoro 6
Shenyang 6
Timisoara 6
Trento 6
Turin 6
Catania 5
Chengdu 5
Chieuti 5
Ercolano 5
Fuzhou 5
Jinan 5
Muizenberg 5
Redwood City 5
Vienna 5
Westminster 5
Cagliari 4
Council Bluffs 4
Montréal 4
Moscow 4
Prato 4
Sant'Agostino 4
Walsall 4
Washington 4
Zhengzhou 4
Chongqing 3
Crotone 3
Freiburg 3
Genoa 3
Gossolengo 3
Groningen 3
North York 3
Nürnberg 3
Obfelden 3
Simi Valley 3
Solbiate Arno 3
Trumbull 3
Verona 3
Wuhan 3
Xian 3
Accadia 2
Totale 10.049
Nome #
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. 122
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage 110
Clinical relevance of silent red blood cell autoantibodies. 103
Efficacy of rituximab treatment in postpartum acquired haemophilia A. 97
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia 94
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain react 91
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults 90
Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2 90
Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia. 90
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant. 89
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes 84
Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223 83
Production of tumor necrosis factor?alpha (TNF) by B?cell chronic lymphocytic leukemia cells. A possible regulatory role of TNF in the progression of the disease. 81
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features 81
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 81
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases 80
Functional analysis and gene expression profile of umbilical cord blood regulatory T cells 80
IL2 treatment for cancer: from biology to gene therapy. 79
Clinical characteristics and outcome of patients with autoimmune hemolytic anemia (AIHA) uniformly defined as primary by a diagnostic work-up 79
Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma 79
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. 78
Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2 resistant autologous acute myeloid leukaemia blasts 78
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 78
The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. 78
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression 78
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. 77
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug nutlin-3: a proposal for clinical application. 76
An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia 75
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. 74
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 74
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. 73
BCR-ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. 73
Angiogenic activity in 1(g)V(H) mutated and unmutated chronic lymphocytic leukemia (CLL): Indications for the therapeutic use of VEGF-signaling inhibitors. 72
Clinical implications of the molecular genetics of chronic lymphocytic leukemia 72
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. 72
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 72
A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia? 71
13q14 Deletion Size and Number of Deleted Cells Both Influence Prognosis in Chronic Lymphocytic Leukemia 71
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome. 71
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 70
Protein Kinase Gene Expression Profiling and In Vitro Functional Experiments Identify Novel Potential Therapeutic Targets in Adult Acute Lymphoblastic Leukemia 69
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 68
null 68
Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia 68
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. 67
Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia 67
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poorresponse to induction therapy. 67
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 66
A broad and integrated diagnostic work-up for a modern management of acute lymphoblastic leukemia (ALL) 66
Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial 66
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile 66
ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype 66
Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia 65
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 65
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications 65
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances 65
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia 65
Cytokines in B cell chronic lymphocytic leukemia. 64
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 64
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 64
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis 64
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia 64
null 64
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy 64
Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up succesfully treated with chemotherapy alone 63
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. 63
Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients 63
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 63
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 re-arrangement and the pre-B stage of differentiation, and prognostic implications. 63
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 63
null 62
null 62
Characterization of B- and T-Lineage Acute Lymphoblastic Leukemia by Integrated Analysis of MicroRNA and mRNA Expression Profiles 62
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib 61
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL 61
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 61
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation 60
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders 60
null 60
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors 60
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly 59
Acute promyelocytic leukemia: results of therapy and analysis of 13 cases. 59
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. 59
Thrombocytopenia in acute leukaemia patients treated with IL2: Cytolytic effect of LAK cells on megakaryocytic progenitors. 59
Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin 59
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab 59
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. 59
null 58
New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia 58
null 58
Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients 57
The changing scene of adult acute lymphoblastic leukemia 57
Interleukin 2 in the management of hematologic malignancies. 57
Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission 57
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia 57
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features 56
Use of the MTT chemosensitivity assay in B cell chronic lymphocytic leukemia. 56
Totale 7.027
Categoria #
all - tutte 35.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.416

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.334 0 0 0 0 0 0 0 0 0 266 574 494
2019/20203.481 489 111 23 164 344 463 471 402 368 347 188 111
2020/20211.001 111 157 41 84 41 49 35 126 118 116 94 29
2021/20223.366 26 176 270 392 423 81 64 309 222 256 506 641
2022/20233.012 628 671 186 313 282 352 35 201 223 16 77 28
2023/2024861 85 201 51 87 86 163 41 86 12 49 0 0
Totale 14.270